Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products. It aims to provide therapeutic products that address unmet medical needs yet have a lower development risk than is usually associated with new chemical entities. The company's flagship product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein. It operates through a single operating and reportable segment which is focused on developing and commercializing pioneering targeted oncology therapies.
Last trade$0.5091
Day change-$0.0185 (-3.51%)
Day range$0.504 – $0.53
Volume86,005
Market cap$14M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$14.55M
Price / earnings
—
Price / book
0.22×
Price / sales
2.05×
EV / sales
0.56×
EV / EBITDA
-0.06×
Profitability
Earnings per share
-$1.69
Return on assets
-32.53%
Return on equity
-69.47%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.1×
Current ratio
0.84×
Quick ratio
0.4×
Cash ratio
0.33×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$34.87M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for CTXR, quarterly periods
Line item
Q3 FY2026 Jun 30, 2026
Q2 FY2026 Mar 31, 2026
Q1 FY2026 Dec 31, 2025
Q4 FY2025 Sep 30, 2025
Q3 FY2025 Jun 30, 2025
Q2 FY2025 Mar 31, 2025
Q1 FY2025 Dec 31, 2024
Q4 FY2024 Sep 30, 2024
Revenue
$1.49M
$1.67M
$3.94M
$0
$0
$0
$0
$0
Cost of revenue
$491.84K
$328.88K
$789.21K
$0
$0
$0
$0
$0
Gross profit
$1M
$1.34M
$3.15M
$0
$0
$0
$0
$0
Selling, general and administrative
$9.96M
$26.39M
$10M
-$4.04M
$7.17M
$4.79M
$7.91M
-$3.7M
Research and development
$1.05M
$3.35M
$1.6M
$1.64M
$1.62M
$3.77M
$2.13M
$2.91M
Total operating expenses
$12.73M
$33.53M
$12.17M
$8.44M
$8.79M
$11.26M
$10.04M
$11.05M
Operating income
-$11.73M
-$32.19M
-$9.02M
-$8.44M
-$8.79M
-$11.26M
-$10.04M
-$11.05M
Interest expense
-$231.73K
-$33.03K
-$155.54K
-$95.52K
-$172.26K
$0
$0
$0
Income before taxes
-$12.03M
-$28.34M
-$9.13M
-$8.48M
-$8.94M
-$11.25M
-$10.02M
-$10.93M
Income taxes
-$107.35K
-$231.21K
$264.24K
$264.24K
$264.24K
$264.24K
$264.24K
$144K
Net income
-$11.92M
-$28.11M
-$9.39M
-$8.74M
-$9.2M
-$11.51M
-$10.28M
-$11.08M
Net income attributable to common shareholders
-$8.86M
-$21.23M
-$8.22M
-$7.96M
-$8.79M
-$10.92M
-$9.77M
-$11.52M
EBITDA
-$11.73M
-$32.19M
-$9.02M
-$8.44M
-$8.79M
-$11.26M
-$10.04M
-$11.05M
Basic earnings per share
-$0.34
-$0.95
-$0.38
-$0.46
-$0.80
-$1.27
-$1.30
-$1.59
Diluted earnings per share
-$0.34
-$0.95
-$0.38
-$0.46
-$0.80
-$1.27
-$1.30
-$1.59
Recent news
Company coverage with links to the original publishers.
Citius Pharmaceuticals reported its first revenue of $3.9 million in Q1 2026 following the December 2025 launch of LYMPHIR by its majority-owned subsidiary Citius Oncology. The drug, approved for treating relapsed or refractory cutaneous T-cell lymphoma, has begun initial sales through a nationwide distributor network. The company raised $20.9 million in equity financing and is advancing late-stage pipeline candidates Mino-Lok and Halo-Lido while exploring international expansion and combination therapy opportunities.
Citius Oncology reported its first revenue of $3.9 million following the successful December 2025 U.S. commercial launch of LYMPHIR, an FDA-approved immunotherapy for cutaneous T-cell lymphoma. The company established nationwide distribution infrastructure and deployed an AI-enabled commercial platform. Despite positive commercial progress, the company reported a net loss of $5.5 million for Q1 2026 and held $7.3 million in cash as of December 31, 2025.
U.S. stock futures declined slightly on Christmas Eve despite a strong Q3 GDP report showing 4.3% annualized growth. Major indices ended higher on Tuesday, with communication services, IT, and energy stocks leading gains. Several stocks gained attention: UiPath jumped 7% after joining the S&P Midcap 400, Citius Pharmaceuticals rose 8.65% on better-than-expected earnings, Ramaco Resources gained 8% after announcing a $100M buyback, and Multi Ways Holdings surged 62.86% on strong revenue growth.
Citius Oncology closed a registered direct offering and private placement, raising approximately $18 million to support the commercial launch of LYMPHIR and for general corporate purposes.
Citius Oncology raised $18 million through a registered direct offering and private placement to support the commercial launch of LYMPHIR, a novel cancer immunotherapy for cutaneous T-cell lymphoma, with H.C. Wainwright & Co. acting as the exclusive placement agent.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.